Authors' Affiliations: Division of Preventive Oncology, National Center for Tumor Diseases (NCT); German Cancer Research Center (DKFZ), Heidelberg, Germany; International Agency for Research on Cancer (IARC), Lyon, France; and Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington.
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2182-201. doi: 10.1158/1055-9965.EPI-13-0584. Epub 2013 Oct 4.
Metabolomics, the systematic investigation of all metabolites present within a biologic system, is used in biomarker development for many human diseases, including cancer. In this review, we investigate the current role of mass spectrometry-based metabolomics in cancer research. A literature review was carried out within the databases PubMed, Embase, and Web of Knowledge. We included 106 studies reporting on 21 different types of cancer in 7 different sample types. Metabolomics in cancer research is most often used for case-control comparisons. Secondary applications include translational areas, such as patient prognosis, therapy control and tumor classification, or grading. Metabolomics is at a developmental stage with respect to epidemiology, with the majority of studies including less than 100 patients. Standardization is required especially concerning sample preparation and data analysis. In the second part of this review, we reconstructed a metabolic network of patients with cancer by quantitatively extracting all reports of altered metabolites: Alterations in energy metabolism, membrane, and fatty acid synthesis emerged, with tryptophan levels changed most frequently in various cancers. Metabolomics has the potential to evolve into a standard tool for future applications in epidemiology and translational cancer research, but further, large-scale studies including prospective validation are needed.
代谢组学是对生物系统中所有代谢物的系统研究,用于许多人类疾病(包括癌症)的生物标志物开发。在这篇综述中,我们研究了基于质谱的代谢组学在癌症研究中的当前作用。在 PubMed、Embase 和 Web of Knowledge 数据库中进行了文献回顾。我们共纳入了 106 项研究,这些研究涉及 7 种不同样本类型的 21 种不同类型的癌症。代谢组学在癌症研究中最常用于病例对照比较。次要应用包括转化领域,如患者预后、治疗控制和肿瘤分类或分级。代谢组学在流行病学方面还处于发展阶段,大多数研究纳入的患者少于 100 人。需要进行标准化,特别是在样品制备和数据分析方面。在这篇综述的第二部分,我们通过定量提取所有报道的代谢物改变的报告,重建了癌症患者的代谢网络:出现了能量代谢、膜和脂肪酸合成的改变,各种癌症中色氨酸水平变化最频繁。代谢组学有可能演变成未来在流行病学和转化癌症研究中应用的标准工具,但需要进一步开展包括前瞻性验证的大规模研究。